Clinical trials: Venous Thromboembolism
Venous Thromboembolism
Multicenter Registry for Effectiveness Analysis of ActiveCare+S.F.T® Mobile Compression Device for Thrombosis Prevention in Hip and Knee Arthroplasty
Venous thromboembolic events (VTE), either deep vein thromboses or pulmonary emboli, are important complications in patients undergoing knee or hip arthroplasty.
- Trial name
- ACOR (NCT01984190)
- Where
- 10 sites in United States
- Volunteers
- 411 people
- Sponsor
- Medical Compression Systems
Neoplasms, Venous Thromboembolism
National Evaluation of the Adherence to Recommendations of Venous Thrombo Embolism Treatment in Cancer Patients
Treatment of venous thromboembolism in cancer patients is specific and has been validated in trials that favor the use of LMWH (Low Molecular Weight Heparin) instead of VKA (Vitamin K Antagonist) treatment during 6 months.
- Trial name
- CARMEN (NCT01362933)
- Testing
- VTE treatment in cancer patient description
- Where
- 49 sites in France
- Volunteers
- 502 people
- Sponsor
- Floralis
Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
This study is designed to evaluate the efficacy and safety of SHR-2004 injection in preventing postoperative venous thromboembolism in patients undergoing ovarian cancer surgery.
- Trial name
- NCT06220123
- Testing
- SHR-2004, Enoxaparin Sodium Injection; Rivaroxaban Tablets
- Where
- China
- Volunteers
- 225 people
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd
Atrial Fibrillation, Atrial Flutter
Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation
The purpose of this research study is to test an experimental drug ATI-5923 vs Coumadin. The study is intended to demonstrate ATI-5923 is superior to Coumadin for keeping INR values in the desired therapeutic range.
- Conditions
- Atrial Fibrillation, Atrial Flutter, Venous Thromboembolic Disease, Myocardial Infarction
- Trial name
- EmbraceAC (NCT00691470)
- Testing
- ATI-5923, Coumadin (warfarin)
- Where
- 41 sites in United States
- Volunteers
- 600 people
- Sponsor
- ARYx Therapeutics
Venous Thromboembolism
Apixaban for the Acute Treatment of Venous Thromboembolism in Children
To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.
- Trial name
- NCT02464969
- Testing
- Apixaban, Standard of Care
- Where
- 128 sites in United States, Australia and 11 more
- Volunteers
- 229 people
- Sponsor
- Bristol-Myers Squibb
Arthroplasty, Replacement, Prevention of Venous Thromboembolism
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
To supplement the current evidence of the effect of Pradaxa® (dabigatran etexilate) on coagulation parameters, including a calibrated thrombin time test, in patients with moderate renal impairment undergoing elective total hip…
- Conditions
- Arthroplasty, Replacement, Prevention of Venous Thromboembolism, Moderate Renal Impairment (CrCl 30-50 mL/Min)
- Trial name
- NCT01184989
- Testing
- Dabigatran etexilate
- Where
- 10 sites in Austria, Canada and 4 more
- Volunteers
- 142 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany
Researcher in this study want to compare the effectiveness of Rivaroxaban (Xarelto) versus low-molecular-weight heparin (LMWH) and phenprocoumon for the treatment and secondary prevention of venous thromboembolism by evaluating…
- Trial name
- NCT04444804
- Testing
- Rivaroxaban (Xarelto, BAY 59-7939), LMWH and Phenprocoumon
- Where
- Germany
- Volunteers
- 22,153 people
- Sponsor
- Bayer
Venous Thromboembolism
Safety and Efficacy Study of Fitaya Vena Cava Filter
A Multi-center, Randomized Controlled Trial to evaluate the safety and efficacy of Fitaya Vena Cava Filter manufactured by Lifetech Scientific (Shenzhen) Co., LTD. for deep vein thrombosis.
- Trial name
- NCT03691753
- Testing
- Fitaya Vena Cava Filter System, Aegisy Vena Cava Filter
- Where
- 13 sites in China
- Volunteers
- 186 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Pulmonary Embolism, Deep Vein Thrombosis
Angel® Catheter Early Feasibility Clinical Study
The primary objective of this clinical trial is to obtain initial insights into the safety of the Angel® Catheter in critically ill subjects with high risk of venous thromboembolism (VTE) disease AND who are not receiving…
- Conditions
- Pulmonary Embolism, Deep Vein Thrombosis, Venous Thromboembolism
- Trial name
- NCT01847196
- Testing
- Angel® Catheter
- Where
- 4 sites in United States
- Volunteers
- 6 people
- Sponsor
- BiO2 Medical
Venous Thromboembolism
Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery
The primary objective was to demonstrate the dose-response of Semuloparin sodium (AVE5026) for the prevention of Venous Thromboembolism [VTE] in patients undergoing total knee replacement [TKR] surgery.
- Trial name
- TREK (NCT00331838)
- Testing
- Semuloparin sodium, Enoxaparin sodium
- Where
- 19 sites in Argentina, Bulgaria and 17 more
- Volunteers
- 705 people
- Sponsor
- Sanofi
Multiple Myeloma
A Safety and Efficacy Study of Revlimid® 5 mg Capsules in Patients With Relapsed or Refractory Multiple Myeloma Who Have Received Long-term Treatment With it Under the Actual Condition of Use
To understand the safety and efficacy of Revlimid® 5 mg Capsules (hereinafter referred to as Revlimid) in patients with "relapsed or refractory multiple myeloma" (hereinafter referred to as "relapsed or refractory MM") who have…
- Trial name
- NCT02922543
- Where
- Japan
- Volunteers
- 361 people
- Sponsor
- Celgene
Acute Venous and Arterial Thrombotic and Thromboembolic Events, Healthy Volunteers
A Study to Learn About How Safe BAY3018250 is and What Happens to it in Healthy Japanese Men and Adult Participants Aged 18 to 55 Years
Researchers are looking for a better way to treat people who have acute venous and arterial thrombotic and thromboembolic events. These are severe medical problems due to blood clots forming in and blocking blood vessels.
- Trial name
- NCT06562985
- Testing
- BAY3018250 Dose 1, BAY3018250 Dose 2 infusion, BAY3018250 Dose 2 injection
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Bayer
Knee Arthroplasty, Total
FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty
This study was to compare the study drug BAY1213790 to existing therapies, i.e. enoxaparin or apixaban, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).
- Trial name
- FOXTROT (NCT03276143)
- Testing
- Enoxaparin, Apixaban, BAY1213790
- Where
- 54 sites in Bulgaria, Canada and 11 more
- Volunteers
- 813 people
- Sponsor
- Bayer
Venous Thromboembolism
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'.
- Trial name
- ROXI-CATH (NCT06299111)
- Testing
- REGN9933, REGN7508
- Where
- 23 sites in United States, Bulgaria and 4 more
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thromboembolism
Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.
- Trial name
- NCT00641732
- Testing
- TAK-442, Enoxaparin
- Where
- 64 sites in United States, Canada
- Volunteers
- 1,045 people
- Sponsor
- Takeda
Venous Thromboembolism, Secondary Prevention
Safety of Dabigatran Etexilate in Blood Clot Prevention in Children
This open-label, single arm prospective cohort study will assess the safety of dabigatran etexilate in secondary prevention of venous thromboembolism in paediatric patients.
- Trial name
- NCT02197416
- Testing
- dabigatran etexilate
- Where
- 62 sites in United States, Austria and 20 more
- Volunteers
- 214 people
- Sponsor
- Boehringer Ingelheim
Deep Vein Thrombosis, Venous Thromboembolism
Post-Market Celect Platinum Vena Cava Filter and Gunther Tulip Retrieval Set Study
This prospective, observational, post-market study will be performed to collect patient-level data on the Celect Platinum Vena Cava Filter Sets and the Günther Tulip Vena Cava Filter Retrieval Set to confirm continued safety and…
- Conditions
- Deep Vein Thrombosis, Venous Thromboembolism, Pulmonary Embolism
- Trial name
- NCT05881798
- Testing
- Celect Platinum Vena Cava Filter
- Where
- 7 sites in United States, Spain and 1 more
- Volunteers
- 82 people
- Sponsor
- Cook Research Incorporated
Thromboembolism
A Clinical Trial Comparing Efficacy and Safety of Dabigatran Etexilate With Warfarin in Patients With Cerebral Venous and Dural Sinus Thrombosis (RE-SPECT CVT)
This is a multi-center, prospective, international, randomized (1:1), open-label study with two parallel groups. This phase III study is planned to investigate the efficacy and safety of dabigatran etexilate versus dose-adjusted…
- Trial name
- NCT02913326
- Testing
- Dabigatran etexilate, Warfarin
- Where
- 36 sites in France, Germany and 7 more
- Volunteers
- 120 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism
Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery
The objective of this study is to evaluate the safety and efficacy of DU-176b compared with enoxaparin sodium for the prevention of venous thromboembolism in patients after elective hip fracture surgery.
- Trial name
- NCT01181141
- Testing
- DU-176b (edoxaban), Enoxaparin sodium 20mg
- Where
- Japan
- Volunteers
- 92 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Thromboembolism, Deep Vein Thrombosis
Prophylaxis In Venous Thromboembolism In Primary Care, A Pilot Study
The primary objective was to study the clinical benefit with dalteparin sodium in thromboprophylaxis in primary care medical subjects.
- Conditions
- Thromboembolism, Deep Vein Thrombosis, Dalteparin
- Trial name
- NCT00655122
- Testing
- Dalteparin sodium
- Where
- 5 sites in Spain
- Volunteers
- 8 people
- Sponsor
- Pfizer